Milnacipran for Panic Disorder

An open trial, published in International Clinical Psychopharmacology, studied the efficacy of milnacipran in the acute treatment of DSM-IV panic disorder with and without agoraphobia. 31 patients were treated with milnacipran 25 mg twice daily, then 50 mg twice daily until the 10th week. Treatment outcome was measured with the Panic Disorder Severity Scale, Panic Inventory, and the Clinical Global Impression and Hamilton Anxiety Scale. Milnacipran treatment resulted in significant mean reduction in all severity measures, and 58.1% of this sample achieved remission. Researchers suggest that the efficacy of milnacipran for panic disorder merits further study.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17414741

-LS